Evidence map›Paper›PMID 39789280›Full record

ArticleAnnals of surgical oncology2025

Age Matters: Early-Onset Rectal Cancer Exhibits Higher Rates of Pathological Complete Response: A Retrospective Analysis of the Influence of Young Age on Treatment Success in Stage II-III Rectal Cancer.

Annaclara Sileo, Richard Sassun, Jyi Cheng Ng, Sara Aboelmaaty, Ibrahim A Gomaa, Giulio Mari, Nicholas P McKenna, Kristen K Rumer, Kellie L Mathis, David W Larson

Abstract read
PubMed Publisher
In one paragraph

Article in Annals of surgical oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
  4. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Annaclara Sileo *Department of Colon and Rectal Surgery, Mayo Clinic, Rochester, MN, USA.
Richard Sassun *Department of Colon and Rectal Surgery, Mayo Clinic, Rochester, MN, USA.
Jyi Cheng NgDepartment of Colon and Rectal Surgery, Mayo Clinic, Rochester, MN, USA.
Sara AboelmaatyDepartment of Colon and Rectal Surgery, Mayo Clinic, Rochester, MN, USA.
Ibrahim A GomaaDepartment of Colon and Rectal Surgery, Mayo Clinic, Rochester, MN, USA.
Giulio MariDepartment of Laparoscopic and Oncological General Surgery, ASST Brianza, Desio Hospital, Desio, Italy.
Nicholas P McKennaDepartment of Colon and Rectal Surgery, Mayo Clinic, Rochester, MN, USA.
Kristen K RumerDepartment of Colon and Rectal Surgery, Mayo Clinic, Rochester, MN, USA.
Kellie L MathisDepartment of Colon and Rectal Surgery, Mayo Clinic, Rochester, MN, USA.
David W LarsonDepartment of Colon and Rectal Surgery, Mayo Clinic, Rochester, MN, USA. Larson.David2@mayo.edu.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundThe incidence of rectal cancer has decreased overall, but the incidence of early-onset rectal cancer (eoRC) has increased. Early-onset rectal cancer and late-onset rectal cancer (loRC) differ due to phenotypical, genetic characteristics, and higher stage presentations in eoRC. Thus, eoRC patients undergo more aggressive neoadjuvant treatments. This paper was designed to evaluate the impact of age on the pathological complete response rates in sporadic locally advanced rectal cancer.

methodsAll patients with stage II-III rectal cancer who underwent neoadjuvant therapy and curative rectal resection between January 2018 and December 2023 were included and allocated to eoRC (<50 years) and loRC (≥50 years) groups based on their age at diagnosis.

resultsA total of 381 patients were included (93 eoRC and 288 loRC). Preoperative radiological imaging revealed higher clinical nodal staging in the eoRC group (p = 0.002). A higher proportion of eoRC resulted in a pathological complete response compared with loRC (29% vs. 18.8%, p = 0.035). The rate of pathological complete response in eoRC and loRC did not differ between patients treated by total neoadjuvant therapy (TNT) and those treated by standard chemoradiotherapy (29.2% vs. 28.6%, p = 0.95 in eoRC and 21.7% vs. 25.9%, p = 0.097 in loRC). Multivariable analysis resulted in young age of onset (odds ratio 2.68; 95% confidence interval 1.11-6.51; p = 0.029) and KRAS wildtype (odds ratio 3.37; 95% confidence interval 1.25-9.07; p = 0.016) as being independent predictors of pathological complete response.

conclusionsSporadic eoRC and KRAS wildtype tumors are predictive factors for pathological complete response in stage II-III rectal cancer.

Indexed as

Neoadjuvant TherapyRectal NeoplasmsAdultAgedAge FactorsAge of OnsetFemaleFollow-Up StudiesHumansMaleMiddle AgedNeoplasm StagingPrognosisRetrospective StudiesEarly-onset colorectal cancerLate-onset colorectal cancerLocally advanced rectal cancerNeoadjuvant therapyPathological complete responseRectal cancer

Identifiers

PMID39789280

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.